Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit The Road towards Triple Agonists: Glucagon Like Peptide 1, Glucose Dependent Insulinotropic Polypeptide and Glucagon Receptor An Update Structural Biophysics Guided Computational Design of Semaglutide Analogues to Enhance GLP 1R Activation Article (Preprint v1) by Wei Li Qeios